Garlicin CF
On sale on the US market (according to the DSLD)
Nature's Way, food supplement from the US market
Garlicin CF (Nature's Way), a food supplement au code-barres 033674067956, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Nature's Way
- Barcode
- 033674067956
- Form
- Tablet
- One serving
- 1 tablet
- Servings
- up to 3 servings per day
- Other ingredients (in English, as written)
- Cellulose, Dicalcium Phosphate, Sodium Croscarmellose, Stearic Acid, Hypromellose, Titanium Dioxide, Sodium Alginate, Silica, Ethylcellulose, Glycerin, Medium Chain Triglycerides, Oleic Acid, Riboflavin
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin C | Vitamin | 20 mg |
| L-OptiZinc | Other substance | 5 mg |
| Echinacea purpurea (Echinacea purpurea) | Plant | 205 mg |
| Garlic (Allium sativum) | Plant | 105 mg |
| Allicin | Other substance | 960 µg |
| Citrus Bioflavonoid Complex | Other substance | 40 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Garlicin Immune
Entered into DSLD on 25 April 2019. Withdrawn from the US market on 10 December 2021 (according to the DSLD).- Same quantity, different name: Garlic (bulb) powder in this version; Garlic on the displayed label (105 mg)
- Same quantity, different name: Zinc in this version; L-OptiZinc on the displayed label (5 mg)
Official label: Garlicin Immune
Entered into DSLD on 25 January 2018. Withdrawn from the US market on 21 June 2018 (according to the DSLD).- Active ingredient added : Sodium (5 mg)
- Active ingredient added : Zinc (5 mg)
- Active ingredient removed : L-OptiZinc (5 mg)
- Same quantity, different name: Bioflavonoid Complex in this version; Citrus Bioflavonoid Complex on the displayed label (40 mg)
- Same quantity, different name: Garlic powder in this version; Garlic on the displayed label (105 mg)
Official label: Garlicin Immune
Entered into DSLD on 29 December 2014. Withdrawn from the US market on 14 July 2017 (according to the DSLD).- Same quantity, different name: releasing 960 mcg Allicin in this version; Allicin on the displayed label (960 mcg)
- Same quantity, different name: Bioflavonoid Complex in this version; Citrus Bioflavonoid Complex on the displayed label (40 mg)
- Same quantity, different name: Garlic powder in this version; Garlic on the displayed label (105 mg)
- Same quantity, different name: Zinc in this version; L-OptiZinc on the displayed label (5 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Echinacea purpurea
Read the warning, when it applies and the studies cited
ECHINACEA - ECHINACEA PURPUREA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, or an immune system disorder (EMA 2015; Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2015: European Medicines Agency (GB). EMA/HMPC/48704/2014. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. Final. [Accessed 2024 December 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications to suppress the immune system (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
Condition of application: Preparations containing herb top.
Stop use if hypersensitivity/allergy occurs (MHRA 2018; EMA 2015; Kligler 2003; WHO 1999).
Sources cited by Health Canada (5)
- EMA 2015: European Medicines Agency (GB). EMA/HMPC/48704/2014. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. Final. [Accessed 2024 December 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf
- Kligler B. 2003. Echinacea. American Family Physician 67(1):77-80. [Accessed 2024 February 22]. Available from: http://www.aafp.org/afp/2003/0101/p77.html
- MHRA 2018: Medicines and Healthcare products Regulatory Agency (GB). Press release: Echinacea herbal products should not be used in children under 12 years old. [Accessed 2024 December 11]. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20140208035927/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON180627
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Geneva (CHE) : Organisation mondiale de la santé; 1999.
- Garlic
Read the warning, when it applies and the studies cited
Garlic - Allium sativum
Route of administration: Oral
Cautions and warnings
Condition of application: Relief of upper respiratory tract infections and catarrhal (nasal congestion) conditions.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or protease inhibitors (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Nature's Way
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Garlicin CF (Nature's Way): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/33674067956-garlicin-cf-nature-s-way, updated 23 January 2023.